The FDA announced that Gilead Sciences will now resume distribution control of its drug Veklury, or remdesivir, as a treatment for patients with COVID-19 infections. The FDA took over distribution of the drug in May following its authorization for emergency use of the drug at the height of the pandemic.
Gilead resumes distribution control for remdesivir
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.